{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T08:44:48Z","timestamp":1794041088239,"version":"4.8.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","ajkd.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1053\/j.ajkd.2021.05.020","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T01:25:20Z","timestamp":1626312320000},"page":"362-373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease\u2013Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients"],"prefix":"10.1053","volume":"79","author":[{"given":"Angelo","family":"Karaboyas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Muenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas S.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L.","family":"Pisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2021.05.020_bib2","doi-asserted-by":"crossref","first-page":"184321","DOI":"10.1155\/2015\/184321","article-title":"International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data","volume":"2015","author":"Hedgeman","year":"2015","journal-title":"Int J Nephrol"},{"key":"10.1053\/j.ajkd.2021.05.020_bib3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2021.05.020_bib4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.ki.5002287","article-title":"Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics","volume":"74","author":"Goodman","year":"2008","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2021.05.020_bib5","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/ndt\/gfn613","article-title":"Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease","volume":"24","author":"Covic","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2021.05.020_bib6","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2021.05.020_bib7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2021.05.020_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(03)00905-3","article-title":"Bone metabolism and disease in chronic kidney disease","volume":"42","author":"Eknoyan","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2021.05.020_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD)","volume":"7","year":"2017","journal-title":"Kidney Int Suppl (2011)"},{"issue":"5","key":"10.1053\/j.ajkd.2021.05.020_bib10","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/j.ajkd.2014.02.003","article-title":"The DOPPS practice monitor for US dialysis care: potential impact of recent guidelines and regulatory changes on management of mineral and bone disorder among US hemodialysis patients","volume":"63","author":"Tentori","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2021.05.020_bib11","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1523-1755.2005.00185.x","article-title":"Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study","volume":"67","author":"Young","year":"2005","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2021.05.020_bib12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2021.05.020_bib13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2215\/CJN.12941213","article-title":"Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study","volume":"10","author":"Tentori","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2021.05.020_bib14","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.103.057273","article-title":"Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl","volume":"308","author":"Nemeth","year":"2004","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2021.05.020_bib15","first-page":"i29","article-title":"Clinical outcomes in secondary hyperparathyroidism and the potential role of calcimimetics","volume":"1","author":"Cunningham","year":"2008","journal-title":"NDT Plus"},{"issue":"12","key":"10.1053\/j.ajkd.2021.05.020_bib16","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1681\/ASN.2007121320","article-title":"Cinacalcet reduces the set point of the PTH-calcium curve","volume":"19","author":"Valle","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2021.05.020_bib17","first-page":"798","article-title":"Association of cinacalcet adherence and costs in patients on dialysis","volume":"14","author":"Lee","year":"2011","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1053\/j.ajkd.2021.05.020_bib18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12882-019-1355-5","article-title":"Predictors of cinacalcet discontinuation and reinitiation in hemodialysis patients: results from 7 European countries","volume":"20","author":"Fuller","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1053\/j.ajkd.2021.05.020_bib19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000350213","article-title":"Evaluating real-world use of cinacalcet and biochemical response to therapy in U.S. hemodialysis patients","volume":"37","author":"Kilpatrick","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2021.05.020_bib20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12882-015-0174-6","article-title":"Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective new-user cohort design","volume":"16","author":"Reams","year":"2015","journal-title":"BMC Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2021.05.020_bib21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2016.19456","article-title":"Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2021.05.020_bib22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"issue":"7","key":"10.1053\/j.ajkd.2021.05.020_bib23","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.ekir.2019.04.010","article-title":"Etelcalcetide is effective at all levels of severity of secondary hyperparathyroidism in hemodialysis patients","volume":"4","author":"Cunningham","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1053\/j.ajkd.2021.05.020_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213774","article-title":"An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism","volume":"14","author":"Block","year":"2019","journal-title":"PLoS One"},{"issue":"10","key":"10.1053\/j.ajkd.2021.05.020_bib25","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/ndt\/gfz039","article-title":"One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism","volume":"35","author":"Bushinsky","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1053\/j.ajkd.2021.05.020_bib26","first-page":"1066","article-title":"Etelcalcetide in patients on hemodialysis with severe secondary hyperparathyroidism: multicenter study in \u201creal life","volume":"8","author":"Russo","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"2","key":"10.1053\/j.ajkd.2021.05.020_bib27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000496562","article-title":"Improved control of secondary hyperparathyroidism in hemodialysis patients switching from oral cinacalcet to intravenous etelcalcetide, especially in nonadherent patients","volume":"48","author":"Xipell","year":"2019","journal-title":"Blood Purif"},{"issue":"3","key":"10.1053\/j.ajkd.2021.05.020_bib28","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/ckj\/sfaa005","article-title":"Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics","volume":"14","author":"Arenas","year":"2020","journal-title":"Clin Kidney J"},{"issue":"suppl 74","key":"10.1053\/j.ajkd.2021.05.020_bib29","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1046\/j.1523-1755.2000.07413.x","article-title":"The Dialysis Outcomes and Practice Patterns Study (DOPPS): an international hemodialysis study","volume":"57","author":"Young","year":"2000","journal-title":"Kidney Int"},{"issue":"5 suppl 2","key":"10.1053\/j.ajkd.2021.05.020_bib30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0272-6386(04)01099-6","article-title":"The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology","volume":"44","author":"Pisoni","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2021.05.020_bib31","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1053\/j.ajkd.2011.03.001","article-title":"The Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor: rationale and methods for an initiative to monitor US bundled dialysis payment system","volume":"57","author":"Robinson","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2021.05.020_bib33","doi-asserted-by":"crossref","first-page":"278-295","DOI":"10.1177\/0962280210395740","article-title":"Review of inverse probability weighting for dealing with missing data","volume":"22","author":"Seaman","year":"2013","journal-title":"Stat Methods Med Res"},{"key":"10.1053\/j.ajkd.2021.05.020_bib34","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/01621459.1979.10481038","article-title":"Robust locally weighted regression and smoothing scatterplots","volume":"74","author":"Cleveland","year":"1979","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"2","key":"10.1053\/j.ajkd.2021.05.020_bib35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2215\/CJN.09550818","article-title":"Variability in cinacalcet prescription across US hemodialysis facilities","volume":"14","author":"Fuller","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2021.05.020_bib36","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000353298","article-title":"Racial differences in clinical use of cinacalcet in a large population of hemodialysis patients","volume":"38","author":"Newsome","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2021.05.020_bib37","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2215\/CJN.05241008","article-title":"Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006","volume":"4","author":"St Peter","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2021.05.020_bib38","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/j.ajkd.2020.02.439","article-title":"Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: a systematic review and network meta-analysis","volume":"76","author":"Palmer","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2021.05.020_bib39","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/ckj\/sfz021","article-title":"Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study","volume":"12","author":"Rottembourg","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1053\/j.ajkd.2021.05.020_bib41","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.2147\/DDDT.S134103","article-title":"Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy","volume":"12","author":"Friedl","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1053\/j.ajkd.2021.05.020_bib42","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.7573\/dic.2020-1-1","article-title":"Cinacalcet adherence in dialysis patients with\u00a0secondary hyperparathyroidism in Lombardy Region: clinical implications and costs","volume":"9","author":"Roggeri","year":"2020","journal-title":"Drugs Context"},{"key":"10.1053\/j.ajkd.2021.05.020_bib43","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"113","year":"2009","journal-title":"Kidney Int Suppl"},{"issue":"26","key":"10.1053\/j.ajkd.2021.05.020_bib44","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2021.05.020_bib45","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/hdi.12503","article-title":"Hemodialysis practice patterns in the Russia Dialysis Outcomes and Practice Patterns Study (DOPPS), with international comparisons","volume":"21","author":"Bikbov","year":"2017","journal-title":"Hemodial Int"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638621007320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638621007320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T02:25:25Z","timestamp":1721010325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638621007320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0272638621007320"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2021.05.020","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease\u2013Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2021.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}